New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:04 EDTSFE, MYGNSafeguard Scientifics expects $40M from Crescendo sale to Myriad
Safeguard Scientifics (SFE) announced that its partner company, Crescendo Bioscience, signed an amended agreement to be acquired by Myriad Genetics (MYGN) for $270M, in cash, minus $25M for the repayment of a loan made to Crescendo by Myriad in 2011. The transaction is expected to close in the fiscal quarter ending March 31, 2014. Safeguard expects to receive approximately $40M in aggregate cash proceeds pending final closing calculations. Safeguard has deployed $11M in Crescendo since December 2012 and has a 13% primary ownership position. Stephen Zarrilli, CEO at Safeguard, said, "Safeguard begins 2014 with tremendous momentum, having recently announced exits transactions for Safeguard’s partner companies Alverix, Inc., NuPathe Inc., ThingWorx, Inc., and now Crescendo Bioscience. We continue to build a robust pipeline of new and exciting opportunities while we are equally focused on identifying well-timed exits to maximize value for our shareholders."
News For SFE;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:09 EDTMYGNMyriad Genetics presents myChoice HRD companion diagnostic test data at ASCO
Subscribe for More Information
07:06 EDTMYGNMyriad Genetics presents myRisk Hereditary Cancer data at ASCO
Myriad Genetics announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use